JENNY LING-YU CHENPan, C.-K.C.-K.PanYU-SEN HUANGTsai, C.-Y.C.-Y.TsaiCHUN-WEI WANGLin, Y.-L.Y.-L.LinSUNG-HSIN KUOShieh, M.-J.M.-J.ShiehMING-JIUM SHIEH2022-02-072022-02-0720210340-7004https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089036100&doi=10.1007%2fs00262-020-02690-w&partnerID=40&md5=e94e5572ad49a84d91034ef0c42245cdhttps://scholars.lib.ntu.edu.tw/handle/123456789/593844C57BL/6 mice implanted in the flank with murine Lewis lung carcinoma cells were randomized into control, anti-angiogenic, anti-PD-L1, radiotherapy (RT), RT + anti-angiogenic, RT + anti-PD-L1, and RT + anti-PD-L1 + anti-angiogenic therapy groups. Immune re[SDGs]SDG3antineoplastic monoclonal antibody; bevacizumab; echo contrast medium; programmed death 1 ligand 1; usphere prime; angiogenesis inhibitor; programmed death 1 receptor; additive effect; animal cell; animal experiment; animal model; animal tissue; antiangiojournal article10.1007/s00262-020-02690-w327614242-s2.0-85089036100